EUVIMEDEUVIMED entdecken
Crossref

Reversible role of MIR654/3P and MIR9/3P in pathogenesis of Epstein-Barr virus–negative, but not Epstein-Barr virus–positive, Burkitt lymphoma

Yu Gong, Wenhua Fu iD

Journal of Leukocyte Biology · 2025

DOI: 10.1093/jleuko/qiae237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Leukocyte Biology, 2025. Verfasst von Yu Gong und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Huainanchaoyang Hospital, No. 15 Renmin South Road, Tianjia 'an District, Huainan 232007, Anhui, China. Hauptthemen laut MEDLINE: MicroRNAs, Burkitt Lymphoma, Herpesvirus 4, Human, Epstein-Barr Virus Infections. Die Arbeit nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The role of MIR654 in Burkitt lymphoma (BL) and whether it impacts expression of MYC and its downstream activated MIR9 is not known. Expression of MYC, MYCN, MYCL, MIR9/3P, MIR654/5P, and MIR654/3P was assessed by quantitative reverse-transcription polymerase chain reaction in biopsy samples from Epstein-Barr virus–negative (EBV−) and EBV+ BL patients and BL cell lines. Effects of modulation of MIR9/3P and MIR654/3P on cell proliferation, apoptosis, and chemosensitivity were evaluated. Luciferase reporter assay was performed to validate the putative target of MIR654/5P. Effects of MIR9/3P and MIR654/3P on tumor burden and disease outcome were evaluated using xenograft model of BL. Expression of MYC, MYCN, and MIR9/3P was higher in all BL patient samples and cell lines. Expression of MIR654/3P was downregulated in EBV− BL patient samples and cell lines compared with either noncancer lymphoid-reactive hyperplasia or EBV+ samples and cell lines. Additionally, MIR654/3P overexpression inhibited cell proliferation, induced apoptosis, and increased chemosensitivity in EBV− BL cell lines. Luciferase reporter assay confirmed that MYC is a target of MIR654/3P in both EBV− and EBV+ BL cell lines; however, the effect of MIR654/3P-mediated targeting of MYC is overridden in EBV+ cells. Administration of MIR654/3P mimic or MIR9/3P antagomir in the xenograft model decreased tumor burden and increased survival. Combined intervention with MIR654/3P mimic and MIR9/3P antagomir had synergistic action on decreasing tumor burden and improving disease outcome. MIR654/3P, as a putative tumor suppressor in EBV− BL, collaborating with MIR9/3P might serve as a therapeutic agent to treat EBV− BL patients in combination with existing chemotherapy and immunotherapy regimes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsBurkitt LymphomaHerpesvirus 4, HumanEpstein-Barr Virus InfectionsHumansAnimalsMiceCell Line, TumorApoptosisGene Expression Regulation, NeoplasticCell ProliferationFemaleMaleProto-Oncogene Proteins c-mycN-Myc Proto-Oncogene Protein

Stichwörter der Autor:innen

MIR654/3PMIR9/3PBurkitt lymphomaMYC

Substanzen

MicroRNAsMIRN92 microRNA, humanProto-Oncogene Proteins c-mycN-Myc Proto-Oncogene Protein

Autor:innen und Institutionen

  • Department of Hematology, Huainanchaoyang Hospital, No. 15 Renmin South Road, Tianjia 'an District, Huainan 232007, Anhui, China.
  • Department of Hematology, First Affiliated Hospital of Anhui Medical University, 218 Jixi Road, Hefei 230022, Anhui, China.
  • Cancer Center, Huainanchaoyang Hospital, No. 15 Renmin South Road, Tianjia 'an District, Huainan 232007, Anhui, China.

ORCID-Profile: Wenhua Fu

Zitieren

APA

Gong, Y., & Fu, W. (2025). Reversible role of MIR654/3P and MIR9/3P in pathogenesis of Epstein-Barr virus–negative, but not Epstein-Barr virus–positive, Burkitt lymphoma. Journal of Leukocyte Biology. https://doi.org/10.1093/jleuko/qiae237

Vancouver

Gong Y, Fu W. Reversible role of MIR654/3P and MIR9/3P in pathogenesis of Epstein-Barr virus–negative, but not Epstein-Barr virus–positive, Burkitt lymphoma. Journal of Leukocyte Biology. 2025. doi:10.1093/jleuko/qiae237

BibTeX
@article{Gong2025,
  author = {Gong, Yu and Fu, Wenhua},
  title = {Reversible role of MIR654/3P and MIR9/3P in pathogenesis of Epstein-Barr virus–negative, but not Epstein-Barr virus–positive, Burkitt lymphoma},
  journal = {Journal of Leukocyte Biology},
  year = {2025},
  doi = {10.1093/jleuko/qiae237}
}
Kostenlos starten →